Arcus kidney cancer data impresses analysts; TriGemX inks a SPAC deal
Source: BioPharma Dive - Latest News
New follow-up results suggest Arcus’ drug might be superior to a marketed Merck medicine. Elsewhere, Eli Lilly and AstraZeneca forged new partnerships.